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ABSTRACT 
Porhyria cutanea tarda (PCT) is a rare, inherited or acquired disorder due to decreased activity or deficiency of 
uroporphyrinogen decarboxylase (UROD), one of the enzymes in the haem synthetic pathway. It is characterized by cutaneous 
manifestations such as erosions, blisters and bulae in the dorsum of the hand, forearm, elbows and knees; and painful indolent 
sores that heal with dyspigmented and scarring lesions. A 25 year old sales man presented with a 7 month history of recurrent 
blistering of the skin of the extremities- hands, elbows, knees and feet which occurred spontaneously or following trivial 
trauma. There was no family history of similar skin symptoms. Examination showed broken and fresh blisters of varying sizes 
with some healed lesions on the dorsum of the hands, over the elbow and knee joints, and toes. Serum ferritin was 360µg/L (40-
340 µg/L), urine uroporphyrinogen was positive (+++) and Hepatitis C antibodies screening was positive. Some improvement of 
the cutaneous lesion was noticed following commencement of therapeutic phlebotomy.  
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RÉSUMÉ  
Porphyrie cutanée tardive (PCT) est rares troubles héritée ou acquis en raison d’activitéréduite ou d’insuffisance 
d’Uroporphyrinogene décarboxylase (UROD), l’une des enzymes dans la voie de synthèse de l’hème .C’est caractérisé par les 
manifestations cutanées telles que :l’érosion, les ampoules et bulae dans le dos de la main, l’avant – bras, les coudes et les 
genoux ; les plaies douloureuses indolentes qui guérissent avec les lésionsdyspigmentees et cicatrisées. Un vendeur de 25ans 
présenté d’une histoire de 7 mois de formations d’ampoules de la peau récurrentes des extrémités – les mains, les coudes, les 
genoux et les pieds qui a eu lieu spontanément ou suite àun traumatisme trivial. Il n’y avait pas d’histoire familiale de 
symptômes de la peau similaires. L’examen a montréles ampoules diverses et fraîches de taille différentes avec des 
lésionscicatrisées sur le dos des mains, au-dessus des coudes et les articulations du genou et les doigts de pieds. Ferritinesérique 
était 360µg/L (40 – 340 µL), Uroporphyrinogene urine était positif (+ + +), et le dépistage de l’hépatite C était positif. Une certaine 
amélioration de la lésioncutanée a été remarquée au commencement des saignées thérapeutiques. 
Mots clés : Porphyrie, les ampoules, virus Hépatite C, Uroporphyrinogene. 
INTRODUCTION 
Porphyrias are a group of metabolic disorders 
resulting from inherited or acquired defects in any of 
the enzymes involved in the synthesis of haem ( 1). 
They are generally rare conditions.(2,3) However 
porphyria cutanea tarda (PCT) is the most common 
type occurring in both sex and all ethnic groups. It is 
due to decreased activity or deficiency of 
uroporphyrinogen decarboxylase (UROD) in the 
 
 
liver.(1,4)  Other factors such as hereditary 
haemochromatosis, alcohol and hepatitis 
have been associated with PCT( 
characterized by cutaneous  manifestations such as 
erosions, blisters and bulae in the dorsum of the 
hand, forearm, and other pressure points such as 
elbows and knuckles of the toes; and painful ind
sores, that heal with dyspigmented and scarring 
lesions (1,7). 
Failure of progression of haem synthesis caused by 
decreased in UROD activity results in accumulation 
of porphyrin by-products first in the liver and 
subsequently disseminate in the plasm
organs. They are excreted primarily in the kidney but 
some are excreted in feces. Porphyrins are 
photoactive molecules and when exposed to light in 
the skin they mediate oxidative damage to 
biomolecular targets and increase mechanical fragilit
causing cutaneous lesions (1,8). 
This case is reported in view of the rarity of this 
disorder and the challenges in it diagnosis and 
management in our environment.  
 
CASE REPORT
E.B is a 25 year old trader who was referred to the 
Dermatology clinic at Bingham University Teaching 
Hospital (BHUTH) with a 7 month history of 
recurrent easy blistering of the skin of the extremities
hands, elbows, knees and feet. The blisters occurred 
spontaneously or following trivial trauma such as 
washing of clothes and wearing tightly fitting shoes. 
There was no associated bleeding, itching, or fever. 
Patient was on vitamins C, A, E and B complex 
prescribed at the general outpatient department 
(GOPD) where he was first seen. He is allergic to 
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chloroquine.  There was no family history of similar 
skin symptoms.  Patient does not drink alcohol or 
smoke cigarette. 
Examination showed a young man with broken and 
fresh blisters of varying sizes with some he
lesions on the dorsum of the hands, over the elbow 
and knee joints, and toes. (see figures 1 and 2) The 
cardiopulmonary system was stable. The liver and 
spleen were not palpable. 
His haematocrit was 40%. The WBC and platelets 
counts were 8.4 x109/L and 220 x 10
Total serum protein, albumin, bilirubin were normal. 
Serum alanine and aspartate transaminases, as well as 
serum urea and creatinine were all within the normal 
limits. Serum ferritin was 360µg/L (40
Urine uroporphyrinogen was positive (+++).  
Histology of the skin lesion showed bullous 
dermatitis as characterized by a keratinizing stratified 
squamous epithelium with intraepidermal bullae 
giving a diagnosis of bullous dermatitis. No notable 
inflammatory reaction. Hepati
screening was positive while HBsAg and HIV 
screening were negative. Other relevant 
investigations such as liver iron stores, UROD 
enzyme assay and genetic studies were not done due 
to lack of facilities. 
Patient was advised to avoid exposing his body to 
sunlight and activities that will traumatize his skin. 
He was also placed on vitamins C and E. There was 
no improvement.  Chloroquine was contraindicated 
as patient was allergic to it.  Weekly 
phlebotomy was commenced on the patient
only 3 sessions and absconded despite some 
improvement.  
                
Fig 2: Porphyria cutanea skin lesion on the elbow of the patient   
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The diagnosis of PCT in this patient we described was 
based on the characteristic cutaneous lesions he 
presented with. This was substantiated by the 
positive urine uroporphyrinogen (+++), the high 
serum ferritin levels and most importantly the 
positive HCV antibodies which has a strong 
association with PCT (5,9).  Diagnosis of PCT is 
confirmed by assaying the UROD enzyme activity in 
red blood cells and carrying out mutation analysis of 
genes encoding UROD especially in the familial 
forms.(4)  Patients with PCT have abnormally high 
levels of porphyrins in their urine, serum or plasma 
specimens and the faecal coproporphyrin fraction  is 
often abnormally high too (7). Other laboratory work 
up  include screening for those factors associated with 
the condition such as HFE gene mutations and iron 
profile.(5)   About 80% of all cases of PCT are acquired 
while the remaining 20% are inherited (8).  Although 
assay  of UROD enzyme or studies of  UROD and 
HFE gene abnormalities were not done, our patient is 
likely to be suffering from acquired or sporadic PCT 
in view of the age of onset and a negative family 
history.  
The care of patients with PCT is multidisciplinary, 
involving consultations with hepatologist, 
haematologist, dermatologist, gynaecologist, 
oncologist etc. (8). Our patient could have benefited 
from further evaluation by a hepatologist but we had 
none in our centre, couple with the patient’s financial 
constraints. Educating the patient about the disease, 
its precipitating factors and the treatment modalities 
available is very important. Patient must avoid 
exposure to sun light, trauma, alcohol or tobacco use 
and may have to discontinue oestrogen therapy if on 
any. The use of topical sun screen creams, 
consumption of vitamin C rich diets and avoidance of 
iron-rich dietary supplements may be of help.(8) 
Therapeutic phlebotomy is one of the treatment 
modalities especially in patients with increased iron 
stores. It involves the removal of one unit of whole 
blood from twice a week to once in 2-3 weeks with the 
aim of reducing the iron stores (1,10). Oral 
Chloroquine phosphate, 125-250mg or  
hydroxychloroquine sulfate, 100-200mg 2-3 times per 
week, is given to patients who cannot tolerate 
therapeutic phlebotomy or whose iron overload is 
relatively mild (11).  Our patient was adequately 
educated and counseled.  However intervention with 
chloroquine was not an option for him because he is 
allergic to it and could cause itching which is a form 
of mild trauma that may exacerbate his condition. 
Therapeutic phlebotomy was the major viable 
treatment option left which he reluctantly accepted 
because he was scared of being bled despite much 
assurance of the minimal risk and likely improvement 
he stands to benefit from the option.  
In conclusion PCT is a rare condition. We hope that 
this report will bring increase awareness on the 
existence of PCT in our environment and hence an 
increased index of suspicion and prompt referral to 
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